Análise de eficácia de acordo com valores de TMB no CheckMate 9LA

O tumor mutation burden (TMB) está potencialmente associado à eficácia clínica dos inibidores de correceptores imunes. Durante o ELCC 2022, foram apresentados os dados de eficácia da combinação de nivolumabe + ipilimumabe + quimioterapia segundo os valores de TMB tanto do tecido tumoral quanto do sangue dos pacientes.

Rapid Readouts: CheckMate 9LA

Arquivo de GBCP - GBCP

Caminhos da Matemática: História, Educação e Aplicações

PDF) Oncogene addiction and tumor mutational burden in non-small-cell lung cancer: Clinical significance and limitations: Tumor mutational burden in NSCLC

First-line nivolumab plus ipilimumab with two cycles of chemotherapy versus chemotherapy alone (four cycles) in metastatic non-small cell lung cancer: CheckMate 9LA 2-year patient-reported outcomes - ScienceDirect

Arquivo de GBCP - GBCP

Untitled

First-line nivolumab plus ipilimumab combined with two cycles of chemotherapy in patients with non-small-cell lung cancer (CheckMate 9LA): an international, randomised, open-label, phase 3 trial - The Lancet Oncology

Ana Moreno (@superanitamix) / X

Long Term Durability and Safety of Dual IO in NSCLC

First-line nivolumab plus ipilimumab combined with two cycles of chemotherapy in patients with non-small-cell lung cancer (CheckMate 9LA): an international, randomised, open-label, phase 3 trial - The Lancet Oncology

PDF) TERAPIA FOTODINÂMICA ATIVADA POR RAIOS X POR INTERMÉDIO DE NANOPARTÍCULAS CINTILADORAS: REVISÃO INTEGRATIVA, Revista Portuguesa de Oncologia

First-line nivolumab plus ipilimumab with two cycles of chemotherapy versus chemotherapy alone (four cycles) in metastatic non-small cell lung cancer: CheckMate 9LA 2-year patient-reported outcomes - European Journal of Cancer

2021 Midyear Review: Non–Small-Cell Lung Cancer - Journal of Oncology Navigation & Survivorship

CheckMate 9LA - Slideset Download - Clin Onc 2020